摘要
目的观察不同剂量瑞舒伐他汀对急性心肌梗死(AMI)患者hs-CRP、LOX-1的影响。方法 60例急性心肌梗死患者随机分为两组,在常规治疗的基础上,常规剂量组口服瑞舒伐他汀10 mg/d,高剂量组口服瑞舒伐他汀20 mg/d,连续服药4周。30例健康体检患者作为对照组。比较治疗前各组hs-CRP、LOX-1水平,治疗组治疗前后hs-CRP、LOX-1、血脂水平,并监测其不良反应。结果与正常健康人相比较,AMI患者hs-CRP、LOX-1水平均明显升高(P<0.05),治疗4周后,治疗组hs-CRP、LOX-1、血脂水平均较治疗前明显降低(P<0.05),其中高剂量组较常规剂量组降低更明显(P<0.05)。结论 AMI患者早期使用较大剂量瑞舒伐他汀20 mg/d能显著降低患者hs-CRP、LOX-1、血脂水平,增加剂量能进一步增强其效果。
[Objectives] To study the effects of different doses of Rosuvastatin on hs-CRP and LOX-1 levels of patients with acute myocardial infarction （AMI）. [ Methods ] 60 patients with AMI were randomly assigned to two groups, with 30 patients in each group. All patients were treated with standard treatment, patients in standard-dose group were orally administrated with 10 mg/d of Rosuvastatin, and patients in high-dose group received 20 mg/d of Rosuvastatin for 4 weeks. Forty healthy people were selected as control group. Hs-CRP and LOX-1 levels were compared between control group and AMI group at the baseline. The same indicator and blood lipid in two groups were comparative study after treatment. Adverse effects were also collected. [Results] The level of hs-CRP and LOX-1 in patients with AMI increased significantly （P 〈0.05） compared to the control group. While after 4-week＇s treatment, the same indicator and blood lipid in two group significantly decreased （P 〈0.05）, and high-dose group achieved a better therapeutic effect （P 〈0.05）. [ Conclusions ] Early use of higher doses of Rosuvastatin 20 mg/d can significantly reduce the levels of hs-CRP, LOX-1 and blood lipid, and with dose-related.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2014年第9期62-64,共3页
China Journal of Modern Medicine
基金
国家级临床重点专科建设项目经费资助
关键词
急性心肌梗死
超敏C反应蛋白
血凝素样氧化低密度脂蛋白受体-1
acute myocardial infarction （AMI）
high-sensitivity C-reactive protein （hs-CRP）
lectin-like oxidizedlow density lipoprotein receptor-1 （LOX-1）
